Refine
Has Fulltext
- yes (7)
Is part of the Bibliography
- yes (7)
Document Type
- Journal article (7) (remove)
Language
- English (7)
Keywords
- PET (3)
- sarcoidosis (2)
- CXCR4 (1)
- DOTATOC (1)
- ECG (1)
- PRRT (1)
- SSTR (1)
- ZDF rats (1)
- [\(^{68}\)Ga] pentixafor (1)
- \(^{18}\)F-FDG (1)
Institute
- Medizinische Klinik und Poliklinik I (6)
- Klinik und Poliklinik für Nuklearmedizin (5)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (1)
- Institut für Klinische Transfusionsmedizin und Hämotherapie (1)
- Institut für Pharmazie und Lebensmittelchemie (1)
- Medizinische Klinik und Poliklinik II (1)
- Pathologisches Institut (1)
- Physikalisches Institut (1)
EU-Project number / Contract (GA) number
- 701983 (1)
Sarcoidosis is a multisystem granulomatous disorder of unknown etiology that can involve virtually all organ systems. Whereas most patients present without symptoms, progressive and disabling organ failure can occur in up to 10% of subjects. Somatostatin receptor (SSTR)-directed peptide receptor radionuclide therapy (PRRT) has recently received market authorization for treatment of SSTR-positive neuroendocrine tumors.
Methods:
We describe the first case series comprising two patients with refractory multi-organ involvement of sarcoidosis who received 4 cycles of PRRT.
Results:
PRRT was well-tolerated without any acute adverse effects. No relevant toxicities could be recorded during follow-up. Therapy resulted in partial response accompanied by a pronounced reduction in pain (patient #1) and stable disease regarding morphology as well as disease activity (patient #2), respectively.
Conclusion:
Peptide receptor radionuclide therapy in sarcoidosis is feasible and might be a new valuable tool in patients with otherwise treatment-refractory disease. Given the long experience with and good tolerability of PRRT, further evaluation of this new treatment option for otherwise treatment-refractory sarcoidosis in larger patient cohorts is warranted.